Comparing IXJ and RSPH: Choosing the Right Healthcare ETF for You

As healthcare continues to be a vital sector within the global economy, investors are increasingly looking for ways to gain exposure through exchange-traded funds (ETFs). Two popular choices are the iShares Global Healthcare ETF (NYSEMKT: IXJ) and the Invesco S&P 500 Equal Weight Health Care ETF (NYSEMKT: RSPH). While both funds target the healthcare sector, they do so through markedly different strategies. Understanding these differences is crucial for investors, especially as they align their portfolios with personal financial goals.

In this article, we will dissect the features, performance metrics, and risk profiles of both IXJ and RSPH. Through a detailed comparison, we aim to guide you in deciding which healthcare ETF might be the best fit for your investment strategy.

Understanding the Basics: IXJ vs. RSPH

Before diving into performance metrics, it’s essential to understand the fundamental structures of these ETFs. The primary distinction lies in their weighting methodologies.

Market-Cap Weighted vs. Equal-Weighted

IXJ employs a traditional market-capitalization weighting strategy, meaning that larger companies have a more significant impact on the fund's performance. This ETF includes 110 global securities, predominantly focusing on well-established pharmaceutical companies. Conversely, RSPH utilizes an equal-weighted strategy, giving each of its 60 holdings roughly the same allocation in the portfolio. This approach reduces the influence of mega-cap companies, allowing smaller, potentially faster-growing firms to have more sway.

Performance Metrics: A Side-by-Side Comparison

When comparing these two ETFs, several key performance indicators can provide insights into their respective strengths and weaknesses. Here’s a quick overview:

• Expense Ratio: Both IXJ and RSPH have an identical expense ratio of 0.40%, making them relatively cost-effective options.
• 1-Year Return: As of July 20, 2026, RSPH boasts a return of 21.01% compared to IXJ’s 18.29%.
• Dividend Yield: IXJ offers a more attractive dividend yield of 1.47%, while RSPH yields 0.70%.
• Beta: RSPH has a beta of 0.81, indicating a higher volatility compared to IXJ’s 0.52.
• AUM (Assets Under Management): IXJ has significantly more assets, at $3.8 billion, compared to RSPH’s $704.8 million.

Risk Assessment: What to Expect

Risk is an inherent part of investing, and understanding the risk profiles of IXJ and RSPH can help investors better align their choices with their risk tolerance.

Max Drawdown and Volatility

The maximum drawdown over the past five years has been 21.95% for RSPH, compared to 18.14% for IXJ. This indicates that RSPH has experienced larger price declines during market downturns, reflecting its more aggressive growth focus. The higher beta also suggests that RSPH is generally more sensitive to market fluctuations, making it a more volatile investment.

Portfolio Composition: What’s Inside?

Understanding what stocks are included in each ETF can offer more context on their potential performance.

Key Holdings

IXJ's portfolio is heavily weighted towards large-cap pharmaceutical companies, with top holdings including:

• Eli Lilly and Co. (10.9%)
• Johnson & Johnson (7.0%)
• AbbVie (5.1%)

In contrast, RSPH's equal-weighted strategy means that its top positions are smaller, high-growth companies, such as:

• Moderna (2.5%)
• Bio-Techne Corp. (2.2%)
• Charles River Laboratories International (2.0%)

Who Should Invest in Each ETF?

Ultimately, the decision between IXJ and RSPH should be influenced by your investment strategy and financial goals.

Consider Your Financial Goals

If you are a conservative investor looking for stability and income, IXJ’s higher dividend yield and focus on established healthcare companies may be more appealing. Its defensive characteristics make it suitable for retirees or those seeking steady cash flow from dividends.

On the other hand, if you are willing to accept higher volatility for the potential of greater returns, RSPH may be the better choice. Its focus on smaller, faster-growing companies could lead to significant gains, especially if these companies continue to expand.

Key Takeaways

• IXJ uses a market-cap weighting strategy, while RSPH employs an equal-weight strategy.
• Both ETFs have identical expense ratios of 0.40%.
• IXJ offers a higher dividend yield, making it attractive for income-focused investors.
• RSPH has shown higher returns but carries more risk and volatility.
• Your choice should align with your personal investment goals and risk tolerance.

Frequently Asked Questions

What is the main difference between IXJ and RSPH?

The primary difference lies in their weighting strategies. IXJ uses a market-capitalization approach, giving larger companies a greater influence on the ETF's performance, while RSPH employs an equal-weight strategy that treats all companies equally, thus providing more exposure to smaller, potentially high-growth firms.

Which ETF is better for conservative investors?

For conservative investors, IXJ is likely the better choice. Its focus on established pharmaceutical companies and higher dividend yield make it a more stable investment, suitable for those seeking consistent income and lower volatility.

Can I invest in both IXJ and RSPH?

Yes, investing in both IXJ and RSPH can provide a balanced exposure to the healthcare sector. By holding both, investors can benefit from the stability of IXJ and the growth potential of RSPH, thus diversifying their healthcare investments.

How do I choose the right ETF for my portfolio?

Choosing the right ETF depends on your financial goals, risk tolerance, and investment horizon. Assess whether you prioritize stability and income or growth potential, and evaluate how each ETF aligns with those objectives. Additionally, consider the overall diversification of your portfolio to ensure a balanced approach.

Disclaimer: This content is educational and not financial advice.